A new class of wet AMD therapeutics

新型湿性 AMD 疗法

基本信息

批准号：
10691697
负责人：
Elizabeth Moran
金额：
$ 39.13万
依托单位：
UNIVERSITY OF MISSOURI KANSAS CITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10691697
关键词：
Acetates Acetone Adoptive Transfer Affect Age Age related macular degeneration Animals Anti-Inflammatory Agents Antiinflammatory Effect Basic Science Benchmarking Binding Biological Assay Blindness Blood Circulation Cadaver Cell Respiration Cells Choroid Choroidal Neovascularization Clinical Research Complication Conditioned Culture Media Conflict (Psychology)Coupled Data Disease Economically Deprived Population Elderly Endothelial Cells Exudative age-related macular degeneration Eye Fatty Acids Foundations G-Protein-Coupled Receptors Genes Genetic Polymorphism Glycolysis Immune In Vitro Incidence Inflammation Inflammatory Intervention Invaded Ketone Bodies Ketones Ketosis Kinetics Knowledge Lasers Lead Left Lesion Link Liver Metabolic Metabolism Microglia Modeling Mus Natural Immunity Oxides Pathology Patient Noncompliance Patients Phenotype Play Population Process Retina Risk Role Severities Testing Therapeutic Time Treatment Efficacy Underserved Population VLDL receptor Vision Work angiogenesis beta-Hydroxybutyrate bevacizumab cell type cost dietary druggable target genome wide association study health care delivery health disparity immunoregulation legally blind macrophage macula neovascularization neutrophil new therapeutic target preservation recruit single-cell RNA sequencing standard of care therapy development

项目摘要

ABSTRACT Advanced neovascular age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV), in which neovessels originating from the choroid invade the macula. CNV causes permanent central blindness if left untreated and is the most sight-threatening pathology of AMD. The present application will investigate the efficacy and regulatory mechanisms for a new class of CNV therapeutics. Anti- VEGF therapies are the standard of care for CNV and can preserve central vision if administered on an indefinitely recurring basis but have reached their therapeutic threshold. Moreover, these therapies are costly and must be injected intravitreally, increasing the risk of complications and patient noncompliance, and limiting availability of treatment to economically disadvantaged patients affected by disparities in health care delivery. The present application has the potential to identify new therapeutics and druggable targets for CNV, particularly those that can be administered systemically rather than intravitreally, and are thus more accessible to underserved populations.

抽象的晚期新生血管性年龄相关性黄斑变性（AMD）的特征是脉络膜新生血管形成（CNV），其中源自脉络膜的新生血管侵入黄斑。 CNV 原因如果不及时治疗，将导致永久性中心失明，这是 AMD 中最威胁视力的病理。现在的该应用将研究一类新型 CNV 疗法的功效和调节机制。反对- VEGF 疗法是 CNV 的标准治疗方法，如果进行治疗，可以保留中央视力。无限期复发的基础，但已达到治疗阈值。此外，这些疗法的费用昂贵并且必须进行玻璃体内注射，增加了并发症和患者不依从性的风险，并限制了为受卫生保健提供差异影响的经济弱势患者提供治疗。本申请有可能确定 CNV 的新疗法和药物靶标，特别是那些可以全身给药而不是玻璃体内给药的药物，因此更容易获得服务不足的人群。